“Latest Stem Cells News”

If you have done any research on stem cell treatments abroad, you will undoubtedly read negative articles like this one on CNN from the mainstream media saying these companies are promising cures and are preying on the desperate, that these companies are selling “snake oil”   Nothing could be further from the truth.

The stem cell companies and stem cell doctors that are part of the Repair Stem Cell Institute offer patients a good chance at an improvement in the patient’s quality of life- they don’t offer nor promise cures.  Patients going to these stem cell therapy treatment centers abroad know this.

Unfortunately, the United States and their FDA don’t give these patients any other options.  Are they able to use their own stem cells to help their multiple sclerosis or heart disease-  Stem Cells that have been proven safe in thousands of studies? No.  What is one to do then?  These patients must go abroad for the only treatment that can help their disease or condition.

Here is a sampling of what some of these companies  affiliated with the Repair Stem Cell Institute tell their patients:

From Stem Cells China:

It’s not a cure. It’s about quality of life. Every day I see inquiries begin like this: “Can stem cells cure…?” Everyone should know the answer to that one right away. No. No known therapy utilizing stem cells can cure any medical condition. Not one.

A cure would rewrite the broken code of your genome. A cure would rewind the debilitating progression of a neuro-degenerative disease to the moment before onset. A cure would fix all the wrongs of a baby’s challenged birth. We eagerly await the development of cures and their accessibility to patients in need.

So why are people receiving stem cell therapy today? Therapies involving adult stem cells today are providing quality of life improvements for many patients. It’s no cure. Just as painkillers are not a cure for pain. They improve our quality of life if we feel pain.

But who would deny that painkillers are still worthwhile for extreme pain? Many doctors in the West are saying that they don’t have enough proof that stem cells are improving quality of life for patients. In the meantime, patients are busy coming to China and China’s stem cell clinics are busy offering the chance for quality of life improvements where none else would exist. We encourage you to explore the therapies being offered today.

From Dr. Shimon Slavin, Israel, helping people like Louis Zylstra and Arndt Roehlig

However, we have some positive and most encouraging evidence that the cells we inject may be of benefit, especially as evidenced in some patients with multiple sclerosis as well as based on the first patient we treated with spinal injury that seemed to have somewhat improved. The good news is that there are no side effects at all so there is no risk and nothing to lose (except money…). I would like to stress that since we are in very early stages of our research, nothing can be said about the clinical efficacy of our approach.  However, on the other hand, I do understand that patients in need cannot wait for all the answers to be solved and this is why we agree to offer experimental procedures for patients that understand the experimental nature of our program and consent to try and explore new treatment options.

From Dr. Roberto Fernandez Vina– For doctors who say that current stem cell therapies are “unproven,” Dr. Fernandez Viña has the following response:

“How many patients must to be treated to say this is a cure? How many patients must die waiting for the word “cure?”

A lot of diseases are not totally cured with drugs but the laboratories talk about curing (HIV, Tuberculosis and a lot of malignant deseases). They say that the drugs “cure” but in reality the drugs improve the quality of life. Stem cells “cure” in the same sense. If a person is dying of diabetes and we improve the prognosis and he no longer needs insulin injections, we increase the C peptide, decrease the HbA1c, decrease protein in the urine, decrease the risk of amputation or kidney failure, in my book that is a “cure.”

From Richard Humphries, with multiple sclerosis and a stem cell recipient from Cell Medicine in Costa Rica:

I’m case study #1 in the paper (Multiple Sclerosis Study) just released and have had two stem cell treatments in Costa Rica where they promise nothing but deliver wonderful results. Secondary Progressive Multiple Sclerosis patients can’t wait on historical data. Time is not on our side but stem cells improved my quality of life and the follow up MRI looks excellent.

From the X cell Center in Germany:

Even if not all of the interactions have been conclusively researched to date, the status of the current medical insights has indeed reached a level that allows the non- hazardous treatment with adult stem cells and puts medical professionals in a position to assume responsibility for its use.

Given the proven treatment success of regenerative medicine, the question of whether more research is needed prior to therapeutic use has already been answered.

Those who nevertheless demand stem cell therapy be postponed until we know more about it are taking away patients’ rights to make their own decisions as they search for medical solutions – for the kind of help stem cell therapy does offer.

Incoming search terms:

The latest developments in molecular biology in the prenatal diagnostic field, particularly regarding preserving stem cells extracted from amniotic liquid, were the focus of the latest S.I.Di.P conference (Italian Society of Prenatal Diagnosis and Maternal Fetal Medicine).

After a greeting from S.I.Di.P President Claudio Giorlandino and President of the Italian Gynecology and Obstetrics Society Giorgio Vittori, Professor Giuseppe Simone, the head of the Biocell Center in Busto Arsizio (VA), the first Italian center able to treat and store stem cells extracted from the amniotic liquid in liquid nitrogen, opened the conference.

“In the next five to ten years,” explained Professor Simoni, “scientific research will have developed therapy based on amniotic stem cells. They are very similar to embryonic stem cells, they are multipotent and young, and this means that they are preferable to embryonic stem cells.

Preserving them creates no risk and the embryo is not sacrificed. Investing into research in this field is an obligation to humanity. There are so many possibilities and the research into amniotic stem cells to treat diseases represents the new frontier for research in the third millennium.

Researchers hope that they can be used to combat many terrible diseases, as well as in reconstructive surgery, and to treat nerve system diseases.”

Stem cells derived from the amniotic liquid are able to differentiate into various tissues, including bone, fat, nerve, cartilage, muscle, hematopoietic tissue, and offer a wide range of clinical applications.

“The future,” continued Simoni, “is research into these types of stem cells, which many research groups, including research teams from Italy, are studying. Preserving them, from anyone who has already decided to undergo amniocentesis is a golden opportunity to donate a precious gift to the future: the gift of life itself. Cryoconservation will allow us to be ready when scientific progress achieves further developments, which will come soon.”

Incoming search terms:

Cellular Dynamics International‘s disclosure Wednesday that its researchers have generated stem cells from ordinary human blood samples holds enormous promise in the emerging field of personalized medicine.

The promise in the long term is that, by giving a vial or two of blood, we could all have our own personal stem cells to deploy in the event of a spinal cord injury or the onset of Parkinson’s disease or many other now-incurable diseases.

Cellular Dynamics is the first company to say it can make stem cells from something as readily available, and so representative of human diversity, as blood.

“This stuff sounds like science fiction, but it’s science fact – and we’re doing it in a lab in Madison,” said Bob Palay, the Madison biotech company’s chairman and chief executive.

The discovery will allow the company in the near term to more easily provide a diverse mix of stem cells to researchers to help them understand the basis of disease and how to treat it, he said.

“It opens up all human tissue cells, in all human diversity, to pharmaceutical and academic researchers. It’s so huge, and so few people understand it,” Palay said.

The stem cells, which scientists refer to as induced pluripotent stem cells, or iPS cells, have all the characteristics of embryonic stem cells. They can turn into beating heart cells, liver cells or any other tissue cells in the body.

“From my knowledge of the market, there are companies out there that may be supplying a particular or specific cell type and offering it to industry, but CDI is doing it with a large suite of cells,” said Andy DeTienne, licensing manager for stem cells at the Wisconsin Alumni Research Foundation.

The foundation holds valuable patents on stem cell work done at the University of Wisconsin-Madison and has an ownership stake in Cellular Dynamics.

The company started out selling stem cell-derived heart cells to Roche and other pharmaceutical companies to help them test the toxicity of drugs.

The company has said it hopes to industrialize production of human cell types for research and create a bio-bank in which people could store stem cells engineered from their DNA for use in personalized therapies or in testing reactions to drugs.
Expanded deal with Roche

Cellular Dynamics said this month that it expanded its drug development testing agreement with Roche so that it will be supplying the drug industry giant with more iPS heart cells and other types of cells over the next two years. The companies also will collaborate to perform various tests on the cells.

Cellular Dynamics was formed in 2004 by stem cell pioneer James Thomson and three other UW researchers. The company has 65 employees and finished ramping up its stem cell production facility in June, Palay said. Cellular Dynamics has sales in the “multimillions” of dollars, he said.

Given its early lead in the industry and the additional products Cellular Dynamics is developing, DeTienne said he expects revenue to snowball.
Cellular Dynamics raised $18 million from mostly Wisconsin-based investors late last year.
Palay declined to comment about whether the company is trying to raise more financing.

from JSonline

Incoming search terms:

Kathrin Plath

UCLA researchers have found that embryonic stem cells and skin cells reprogrammed into embryonic-like cells have inherent molecular differences, demonstrating for the first time that the two cell types are clearly distinguishable from one another.

The data from the study suggest that embryonic stem cells and the reprogrammed cells, known as induced pluripotent stem (iPS) cells, have overlapping but still distinct gene expression signatures. The differing signatures were evident regardless of where the cell lines were generated, the methods by which they were derived or the species from which they were isolated, said William Lowry, a researcher with the Broad stem cell research center and a study author.

“We need to keep in mind that iPS cells are not perfectly similar to embryonic stem cells,” said Lowry, an assistant professor of molecular, cell and developmental biology. “We’re not sure what this means with regard to the biology of pluripotent stem cells. At this point our analyses comprise just an observation. It could be biologically irrelevant, or it could be manifested as an advantage or a disadvantage.”

The study appears in the July 2 issue of the journal Cell Stem Cell.

The iPS cells, like embryonic stem cells, have the potential to become all of the tissues in the body. However, iPS cells don’t require the destruction of an embryo. Some have touted iPS cells as replacements for embryonic stem cells. However, this study finds they are not identical as previously surmised. Researchers have maintained it is important to continue to study both cell types.

The study was a collaboration between the labs of Lowry and UCLA researcher Kathrin Plath. Lowry and Plath were among the first scientists worldwide and the first in California to reprogram human skin cells into iPS cells. The researchers performed microarray gene expression profiles on embryonic stem cells and iPS cells to measure the expression of thousands of genes at once, creating a global picture of cellular function.

Lowry and Plath noted that, when the molecular signatures were compared, it was clear that certain genes were expressed differently in embryonic stem cells than they were in iPS cells. They then compared their data to that stored on a National Institutes of Health data base, submitted by laboratories worldwide. They analyzed that data to see if the genetic profiling conducted in other labs validated their findings, and again they found overlapping but distinct differences in gene expression, Lowry said.

Incoming search terms:

Stem cell researchers have a lot of big dreams, and one is to someday regenerate damaged hearts. That is still many years away from becoming a commercial reality, if ever, but a few University of Washington scientists have formed a new company that hopes to make cells that can replace pacemakers, and someday rebuild damaged heart tissue that people are left with after heart attacks.

The company, Bellevue, WA-based Beat BioTherapeutics, is the brainchild of Chuck Murry and Michael Laflamme, a pair of UW stem cell researchers, and UW bioengineering professor Buddy Ratner. It has roots in about a decade of research, with $20 million of funding from the National Institutes of Health, Ratner says. No venture capitalists have chipped in to carry this work forward through the early phases of development, although the fledgling company has found another way forward through a partnership with the Bellevue, WA-based Hope Heart Institute, that will provide it with services and support, says CEO Stephen Quinn.

The basic concept of BeatBio, as it’s known for short, is a marriage of stem cell biology and biomedical engineering. Murry and Laflamme’s work has at least partly paved the way for the company to reprogram adult skin cells, to give them vast potential to become other types of cells, like those of the heart. BeatBio specifically wants to direct these cells to become cardiac pacemaker cells, and also cardiomyocytes, the cells that make up heart ventricles. Importantly, scientists have shown the cells can be kept proliferating over time in live animals, Ratner says (…)

“Somebody’s got to be crazy enough to take stem cell therapies to the market,” Quinn says.

Read more on xconomy

Incoming search terms:

BRITISH face surgeons are to grow new skull, cheek and jaw bones on patients’ backs using their own stem cells.
The surgeons, from Barts and the London NHS Trust, hope to use the technique to help people whose facial bones have been destroyed by cancer or injury.

Four patients are awaiting the treatment, which the surgeons believe could eventually become a less risky alternative to face transplants. Two are cancer victims and two have had accidents.
The team, led by Iain Hutchison, will make the first attempt to grow replacement bone from a patient’s own stem cells in Britain.

The procedure involves constructing a mould in the shape of the bone required and filling it with the patient’s bone marrow. This contains stem cells which can be persuaded to grow into different types of tissue. A genetically modified protein coaxes the stem cells to grow into bone. The mould is then inserted into the patient’s back muscles below the shoulder blade where it establishes a blood supply from the patient.

It is left to grow there for three to six months when it will be transplanted onto the patient’s face.
According to Hutchison, the stem cell procedure also has advantages over existing techniques of removing bones from other parts of the body. (…)

Read full article on Times Online

Incoming search terms: